Navigation Links
China Biologic Products Announces First Quarter 2010 Results
Date:5/17/2010

TAI'AN, China, May 17 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today reported financial results for its first quarter ended March 31, 2010.

    First Quarter 2010 Highlights

    -- Revenues increased 28.1% year-over-year to $27.1 million
    -- Gross profit rose 35.9% year-over-year to $20.3 million, representing a
       gross margin of 74.9%, as compared to 70.6% a year ago
    -- Operating income grew 31.4% to $13.2 million
    -- GAAP net income attributable to controlling interest was $10.6 million,
       or $0.41 per diluted share, including a $3.8 million non-cash gain from
       change in the fair value of derivative liabilities
    -- Excluding the non-cash gain, interest on convertible notes and non-cash
       employee compensation, non-GAAP adjusted net income was $7.5 million or
       $0.28 per diluted share, a 60.6% increase from $4.7 million or $0.22
       per diluted share a year ago

"We are pleased to report a strong start in 2010 with a robust 28% top-line and 61% adjusted bottom-line growth in the first quarter," said Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic. "In addition to the strong financial performance, we have begun the exp
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. China Sky One Medicals CEO Receives Award For "Leadership Excellence In Innovation"
2. China Sky One Medical to Attend Investment Conferences in May
3. China Biologic Products to Build Two New Plasma Stations in Shandong Province
4. China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18
5. China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province
6. China Pharma Holdings, Inc. Announces May Investor Conference Participation
7. China Nepstar Chain Drugstore Reports First Quarter 2010 Results on May 19
8. China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and the Fiscal Year Ended March 31, 2010 on June 4, 2010
9. China Pharma Holdings, Inc. Retains CCG Investor Relations
10. China Medical Technologies to Participate in Investor Conferences in May and June 2010
11. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... May 7 Patients treated with the ... at two years, according to interim results from ... a late-breaking clinical trial at the Society for ... Sessions. The prospective, single-arm study is ongoing to ...
... Inc. (NYSE: HRC ) today announced its fiscal 2010 third quarter dividend of ... 6, 2010 , and is payable on June 30, 2010 , to shareholders of record ... , , ABOUT ... Hill-Rom is a leading worldwide manufacturer and ...
Cached Medicine Technology:Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games ... the state to Columbia. This state-level event takes place May ... and Columbia College, and at Hickman High School and Town ... kick off at 7:30 p.m. Friday, May 30 with the ... theme, the Parade of Athletes, the culmination of the statewide ...
(Date:5/21/2013)... Venice Beach, Calif. (PRWEB) May 21, 2013 ... to treating a dual diagnosis of Borderline Personality Disorder ... therapy that is proving to be successful for the ... Saturday, June 1, Alina Gorgorian, Ph.D., clinical director ... treatment in Los Angeles, will provide attendees of ...
(Date:5/21/2013)... autism showed significant improvement after six months of simple ... scents, spoons and sponges, according to UC Irvine neurobiologists. ... enrichment led to notable gains in male subjects between ... in Behavioral Neuroscience . , Study co-authors Cynthia ... one of two groups, balanced for age and autism ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... business process integration solutions, today announced it is the ... by analyst firm 451 Research. The report, “Adeptia Bets ... in-depth review of the company, its strategy, products, pricing, ... are in need of a framework for integration and ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2
... common condition, researchers say , TUESDAY, March 30 (HealthDay News) ... deep vein thrombosis, it is most likely to occur on ... researchers have found. , Dr. Wee-Shian Chan of Women,s ... review, said in a news release that the clots most ...
... Osmosis Day ... business with more than 200,000 of the unique healing bath treatments delivered in a Japanese ... Freestone, CA (PRWEB) ... chicken coop, Osmosis, a day spa in Sonoma County California , has delivered more ...
... from arthritis and osteoporosis to broken bones that won,t ... a key molecular player to keep stem cells in ... makes treatment with the cells in the future more ... the cells, known as mesenchymal (pronounced meh-ZINK-a-mill) stem cells, ...
... and the American Society of Hematology (ASH) have selected ... EHA-ASH Research Exchange Award, which serves to strengthen ties ... Ingmar Bruns is a resident physician and research scientist ... at the University of Dsseldorf in Germany. After graduating ...
... ... Serve Spanish-Speaking Patients , ... (PRWEB) March 30, 2010 -- The HealthLinkRx Institute has announced news dates ... sessions of the Institute’s “Therapy in Spanish” class will be offered in Austin, TX ...
... , TUESDAY, March 30 (HealthDay News) -- Researchers have ... be linked to autism disorders. , "To our knowledge, ... of association between these important genes in brain connections ... of the Wellcome Trust Center for Human Genetics at ...
Cached Medicine News:Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 2Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 3Health News:Promoting healing by keeping skeletal stem cells 'young' 2Health News:Promoting healing by keeping skeletal stem cells 'young' 3Health News:European hematologist receives award to conduct research in US 2Health News:HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists 2
... Olympus has pioneered the ... neurosurgical imaging system, an innovative ... be more efficient and less ... consists of the OME-7000 surgical ...
The Leica MS1 F/MC1 F is designed to mount on the ceiling with a high degree of mobility. Its unique and patented suspension concept assures a superior stability and a perfect and steady microscope i...
... SheerVision surgical magnifying loupes are ... quality optics which provide the healthcare ... and greater depth of field. Each ... in a fully lined wooden box ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
Medicine Products: